Inhibrx Biosciences, Inc. (NASDAQ:INBX – Get Free Report) Director Kimberly Manhard sold 500 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $115.14, for a total value of $57,570.00. Following the sale, the director directly owned 9,500 shares of the company’s stock, valued at approximately $1,093,830. The trade was a 5.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Inhibrx Biosciences Stock Performance
Shares of INBX opened at $111.42 on Friday. The firm has a market cap of $1.64 billion, a P/E ratio of -12.55 and a beta of 3.66. Inhibrx Biosciences, Inc. has a twelve month low of $26.19 and a twelve month high of $155.29. The company has a debt-to-equity ratio of 12.58, a quick ratio of 5.07 and a current ratio of 5.07. The firm’s 50 day moving average price is $98.80 and its two-hundred day moving average price is $93.20.
Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) EPS for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). On average, analysts forecast that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current fiscal year.
Analyst Ratings Changes
Check Out Our Latest Research Report on INBX
Hedge Funds Weigh In On Inhibrx Biosciences
Several hedge funds and other institutional investors have recently made changes to their positions in INBX. Bank of America Corp DE bought a new position in shares of Inhibrx Biosciences during the 2nd quarter worth approximately $79,698,000. BlackRock Inc. acquired a new position in shares of Inhibrx Biosciences in the second quarter valued at $78,261,000. California State Teachers Retirement System lifted its stake in shares of Inhibrx Biosciences by 149,396.5% during the 2nd quarter. California State Teachers Retirement System now owns 734,028 shares of the company’s stock worth $69,549,000 after buying an additional 733,537 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Inhibrx Biosciences by 163.7% during the 4th quarter. Morgan Stanley now owns 1,167,728 shares of the company’s stock worth $92,251,000 after buying an additional 724,872 shares during the period. Finally, Capital Research Global Investors bought a new position in Inhibrx Biosciences in the 4th quarter valued at about $33,304,000. 82.46% of the stock is owned by institutional investors.
About Inhibrx Biosciences
Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.
The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.
Featured Stories
- Five stocks we like better than Inhibrx Biosciences
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
